Study title: Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of European Society of Paediatric Gastroenterology and Nutrition - Vandenplas Y - 1994 (J. Pediatr. Gastroenterol. Nutri. 1994; 18: 413-422) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of European Society of Paediatric Gastroenterology and Nutrition - Vandenplas Y - 1994 (J. Pediatr. Gastroenterol. Nutri. 1994; 18: 413-422) - Publication in Part IC3 - Expert Report - Dupont C - 03/02/1997 -
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Digestive System Diseases [C06] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE | |||||
| ATC code: A02AD01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |